Aquestive Therapeutics, Inc. AQST Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s deferred tax assets, valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s deferred tax assets, valuation allowance?
- Aquestive Therapeutics, Inc. (AQST) reported deferred tax assets, valuation allowance of $113.17M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred tax assets, valuation allowance?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s deferred tax assets, valuation allowance has grown at a 16.0% compound annual growth rate (CAGR), from $84.05M to $113.17M.